Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen

Cancer Letters

Volumn 274, Issue 1, 2009, Pages 118-125

  Argov, Mirit ^a   Kashi, Rina ^b   Peer, Dan ^a   Margalit, Rimona ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b Teva Pharmaceutical Industry   (Israel)

Author keywords

Bevacizumab; Colon cancer; Doxorubicin; Fluoxetine; Multidrug resistance; P glycoprotein

Indexed keywords

BEVACIZUMAB; DOXORUBICIN; FLUOXETINE; GLYCOPROTEIN P;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CHEMOSENSITIZATION; COLON CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATP-BINDING CASSETTE TRANSPORTERS; CELL PROLIFERATION; COLONIC NEOPLASMS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; FLUOXETINE; HUMANS; MICE; MICE, NUDE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; SEROTONIN UPTAKE INHIBITORS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 57849167858     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.09.005     Document Type: Article

References (43)

1. Pasetto L.M., and Monfardini S. Colorectal cancer screening in elderly patients: when should be more useful?. Cancer Treat. Rev. 33 (2007) 528-532
2. Okuno K. Surgical treatment for digestive cancer. Current issues - colon cancer. Dig. Surg. 24 (2007) 108-114
3. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., and Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350 (2004) 2335-2342
4. Iqbal S., and Lenz H.J. Integration of novel agents in the treatment of colorectal cancer. Cancer Chemother. Pharmacol. 54 Suppl. 1 (2004) S32-S39
5. Wang Y., Fei D., Vanderlaan M., and Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7 (2004) 335-345
6. Koo D.H., Lee J.L., Kim T.W., Chang H.M., Ryu M.H., Yook J.H., Oh S.T., Kim B.S., Lee J.S., and Kang Y.K. Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma. Eur. J. Surg. Oncol. 33 (2007) 843-848
7. Roth A.D., Fazio N., Stupp R., Falk S., Bernhard J., Saletti P., Koberle D., Borner M.M., Rufibach K., Maibach R., Wernli M., Leslie M., Glynne-Jones R., Widmer L., Seymour M., and de Braud F. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J. Clin. Oncol. 25 (2007) 3217-3223
8. Schuhmacher C.P., Fink U., Becker K., Busch R., Dittler H.J., Mueller J., and Siewert J.R. Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum. Closing results after 5 years of follow-up. Cancer 91 (2001) 918-927
9. Webb A., Cunningham D., Scarffe J.H., Harper P., Norman A., Joffe J.K., Hughes M., Mansi J., Findlay M., Hill A., Oates J., Nicolson M., Hickish T., O'Brien M., Iveson T., Watson M., Underhill C., Wardley A., and Meehan M. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J. Clin. Oncol. 15 (1997) 261-267
10. Wils J.A., Klein H.O., Wagener D.J., Bleiberg H., Reis H., Korsten F., Conroy T., Fickers M., Leyvraz S., Buyse M., et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin - a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J. Clin. Oncol. 9 (1991) 827-831
11. ®. Biochem. Pharmacol. 75 (2008) 1302-1312
12. Leonard G.D., Fojo T., and Bates S.E. The role of ABC transporters in clinical practice. Oncologist 8 (2003) 411-424
13. Litman T., Druley T.E., Stein W.D., and Bates S.E. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell. Mol. Life Sci. 58 (2001) 931-959
14. Lautier D., Canitrot Y., Deeley R.G., and Cole S.P. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem. Pharmacol. 52 (1996) 967-977
15. Gottesman M.M., Fojo T., and Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2 (2002) 48-58
16. Leslie E.M., Deeley R.G., and Cole S.P. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. 204 (2005) 216-237
17. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., and Gottesman M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5 (2006) 219-234
18. Collett A., Tanianis-Hughes J., and Warhurst G. Rapid induction of P-glycoprotein expression by high permeability compounds in colonic cells in vitro: a possible source of transporter mediated drug interactions?. Biochem. Pharmacol. 68 (2004) 783-790
19. Wan C.K., Zhu G.Y., Shen X.L., Chattopadhyay A., Dey S., and Fong W.F. Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells. Biochem. Pharmacol. 72 (2006) 824-837
20. Peer D., Dekel Y., Melikhov D., and Margalit R. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Cancer Res. 64 (2004) 7562-7569
21. Peer D., and Margalit R. Fluoxetine and reversal of multidrug resistance. Cancer Lett. 237 (2006) 180-187
22. Pusztai L., Wagner P., Ibrahim N., Rivera E., Theriault R., Booser D., Symmans F.W., Wong F., Blumenschein G., Fleming D.R., Rouzier R., Boniface G., and Hortobagyi G.N. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 104 (2005) 682-691
23. Yu S.T., Chen T.M., Tseng S.Y., and Chen Y.H. Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells. Biochem. Biophys. Res. Commun. 358 (2007) 79-84
24. Ohtani H., Ikegawa T., Honda Y., Kohyama N., Morimoto S., Shoyama Y., Juichi M., Naito M., Tsuruo T., and Sawada Y. Effects of various methoxyflavones on vincristine uptake and multidrug resistance to vincristine in P-gp-overexpressing K562/ADM cells. Pharm. Res. 24 (2007) 1936-1943
25. Trock B.J., Leonessa F., and Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J. Natl. Cancer Inst. 89 (1997) 917-931
26. Coley H.M., Verrill M.W., Gregson S.E., Odell D.E., Fisher C., and Judson I.R. Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma. Eur. J. Cancer 36 (2000) 881-888
27. Bates S.E. Drug resistance: still on the learning curve. Clin. Cancer Res. 5 (1999) 3346-3348
28. Boquete A.L., Vargas Roig L., Lopez G.A., Gude R., Binda M.M., Gonzalez A.D., Ciocca D.R., and Bonfil R.D. Differential anthracycline sensitivity in two related human colon carcinoma cell lines expressing similar levels of P-glycoprotein. Cancer Lett. 165 (2001) 111-116
29. Katayama K., Yoshioka S., Tsukahara S., Mitsuhashi J., and Sugimoto Y. Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein. Mol. Cancer Ther. 6 (2007) 2092-2102
30. Xiao J.J., Huang Y., Dai Z., Sadee W., Chen J., Liu S., Marcucci G., Byrd J., Covey J.M., Wright J., Grever M., and Chan K.K. Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dit hia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines. J. Pharmacol. Exp. Ther. 314 (2005) 467-475
31. Uchiyama-Kokubu N., and Watanabe T. Establishment and characterization of adriamycin-resistant human colorectal adenocarcinoma HCT-15 cell lines with multidrug resistance. Anticancer Drugs 12 (2001) 769-779
32. Szepeshazi K., Schally A.V., Halmos G., Armatis P., Hebert F., Sun B., Feil A., Kiaris H., and Nagy A. Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status. Cancer Res. 62 (2002) 781-788
33. Watanabe T., Naito M., Kokubu N., and Tsuruo T. Regression of established tumors expressing P-glycoprotein by combinations of adriamycin, cyclosporin derivatives, and MRK-16 antibodies. J. Natl. Cancer Inst. 89 (1997) 512-518
34. Dako-specification sheet, Monoclonal mouse anti-human p-glycoprotein clone 4E3 PL1502-M3523 (2007).
35. Chauvier D., Kegelaer G., Morjani H., and Manfait M. Reversal of multidrug resistance-associated protein-mediated daunorubicin resistance by camptothecin. J. Pharm. Sci. 91 (2002) 1765-1775
36. Poulain S., Lepelley P., Preudhomme C., Cambier N., Cornillon J., Wattel E., Cosson A., and Fenaux P. Expression of the multidrug resistance-associated protein in myelodysplastic syndromes. Br. J. Haematol. 110 (2000) 591-598
37. de Paiva C.S., Chen Z., Corrales R.M., Pflugfelder S.C., and Li D.Q. ABCG2 transporter identifies a population of clonogenic human limbal epithelial cells. Stem Cells 23 (2005) 63-73
38. Leontieva O.V., Preobrazhenskaya M.N., and Bernacki R.J. Partial circumvention of P-glycoprotein-mediated multidrug resistance by doxorubicin-14-O-hemiadipate. Invest. New Drugs 20 (2002) 35-48
39. Lee H., Lee S.I., Cho J., Choi S.U., and Yang S.I. Synthesis and in vitro evaluation of 1,8-diazaanthraquinones bearing 3-dialkylaminomethyl or 3-(N-alkyl- or N-aryl)carbamoyloxymethyl substituent. Eur. J. Med. Chem. 38 (2003) 695-702
40. Ohishi K., Morinaga Y., Ohsumi K., Nakagawa R., Suga Y., Tsuji T., Akiyama Y., and Tsuruo T. Potentiation of antitumor and antimetastatic activities of adriamycin by a novel N-alkylated dihydropyridine, AC394 and its enantiomers in colon cancer-bearing mice. Cancer Chemother. Pharmacol. 38 (1996) 446-452
41. Pawarode A., Shukla S., Minderman H., Fricke S.M., Pinder E.M., O'Loughlin K.L., Ambudkar S.V., and Baer M.R. Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins. Cancer Chemother. Pharmacol. 60 (2007) 179-188
42. Cookson J., and Duffett R. Fluoxetine: therapeutic and undesirable effects. Hosp. Med. 59 (1998) 622-626
43. www.clinicalTrials.gov, doxorubicin and bevacizumab, 2007.